Efficacy and safety of fenofibric acid in combination with atorvastatin and ezetimibe in patients with mixed dyslipidemia

American Heart Journal

Volumn 160, Issue 4, 2010, Pages 759-766

  Jones, Peter H ^a   Goldberg, Anne C ^b   Knapp, Howard R ^c   Kelly, Maureen T ^d   Setze, Carolyn M ^d   Stolzenbach, James C ^d   Sleep, Darryl J ^d  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BILLINGS CLINIC   (United States)

^d ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; APOLIPOPROTEIN B; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; EZETIMIBE; FENOFIBRIC ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL; AZETIDINE DERIVATIVE; CHOLESTEROL; FENOFIBRATE; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; PYRROLE DERIVATIVE;

ADULT; ARTHRALGIA; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIET THERAPY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; FATIGUE; FEMALE; HEADACHE; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MIXED DYSLIPIDEMIA; MULTICENTER STUDY; MUSCLE SPASM; MYALGIA; NAUSEA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHABDOMYOLYSIS; TRIACYLGLYCEROL BLOOD LEVEL; AGED; ANALOGS AND DERIVATIVES; BLOOD; DOSE RESPONSE; DRUG COMBINATION; DYSLIPIDEMIAS; FOLLOW UP; MIDDLE AGED; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTICHOLESTEREMIC AGENTS; AZETIDINES; CHOLESTEROL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; FEMALE; FENOFIBRATE; FOLLOW-UP STUDIES; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PYRROLES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77957857200     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2010.06.045     Document Type: Article

References (27)

1. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report Circulation 106 2002 3143 3421
2. Assmann G., and Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Munster study Am J Cardiol 70 1992 733 737
3. Assmann G., Schulte H., and Cullen P. Assessing risk of myocardial infarction and stroke: new data from the Prospective Cardiovascular Munster (PROCAM) study Eur J Clin Invest 37 2007 925 932
4. Hokanson J.E., and Austin M.A. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies J Cardiovasc Risk 3 1996 213 219
5. Sarwar N., Danesh J., and Eiriksdottir G. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies Circulation 115 2007 450 458
6. Baigent C., Keech A., and Kearney P.M. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins Lancet 366 2005 1267 1278
7. Davidson M.H., Ballantyne C.M., and Kerzner B. Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia Int J Clin Pract 58 2004 746 755
8. Ballantyne C.M., Abate N., and Yuan Z. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study Am Heart J 149 2005 464 473
9. Fruchart J.C., Sacks F., and Hermans M.P. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia Am J Cardiol 102 10 Suppl 2008 1K 34K
10. Brunzell J.D., Davidson M., and Furberg C.D. Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation J Am Coll Cardiol 51 2008 1512 1524
11. American Heart Association An eating plan for healthy Americans-our American Heart Association diet 2004 AHA Dallas (TX) Publication No. 50-1481A
12. Jones P.H., Davidson M.H., and Kashyap M.L. Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study Atherosclerosis 204 2009 208 215
13. Roth E.M., Rosenson R.S., and Carlson D.M. A phase III study evaluating the efficacy and safety of 135 mg fenofibric acid (ABT-335) in combination with 5 mg rosuvastatin in patients with atherogenic dyslipidemia [ACC abstract 1021-85] J Am Coll Cardiol 53 supplA 2009 A208
14. Mohiuddin S.M., Pepine C.J., and Kelly M.T. Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: a phase 3, randomized, controlled study Am Heart J 157 2009 195 203
15. Goldberg A.C., Bays H.E., and Ballantyne C.M. Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia Am J Cardiol 103 2009 515 522
16. A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators Br Heart J 40 1978 1069 1118
17. WHO cooperative trial on primary prevention of ischaemic heart disease with clofibrate to lower serum cholesterol: final mortality follow-up. Report of the Committee of Principal Investigators Lancet 2 1984 600 604
18. Keech A., Simes R.J., and Barter P. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial Lancet 366 2005 1849 1861
19. Robins S.J., Collins D., and Wittes J.T. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial JAMA 285 2001 1585 1591
20. Goldenberg I., Benderly M., and Sidi R. Relation of clinical benefit of raising high-density lipoprotein cholesterol to serum levels of low-density lipoprotein cholesterol in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial) Am J Cardiol 103 2009 41 45
21. Goldenberg I., Boyko V., and Tennenbaum A. Long-term benefit of high-density lipoprotein cholesterol-raising therapy with bezafibrate: 16-year mortality follow-up of the bezafibrate infarction prevention trial Arch Intern Med 169 2009 508 514
22. Fazio S., and Linton M.F. The role of fibrates in managing hyperlipidemia: mechanisms of action and clinical efficacy Curr Atheroscler Rep 6 2004 148 157
23. Farnier M., Roth E., and Gil-Extremera B. Efficacy and safety of the coadministration of ezetimibe/simvastatin with fenofibrate in patients with mixed hyperlipidemia Am Heart J 153 2007 335.e1 335.e8
24. Elisaf M. Effects of fibrates on serum metabolic parameters Curr Med Res Opin 18 2002 269 276
25. Bays H.E., Jones P.H., and Mohiuddin S.M. Long-term safety and efficacy of fenofibric acid in combination with statin therapy for the treatment of patients with mixed dyslipidemia J Clin Lipidol 2 2008 426 435
26. McKenney J.M., Farnier M., and Lo K.W. Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia J Am Coll Cardiol 47 2006 1584 1587
27. Law M., and Rudnicka A.R. Statin safety: a systematic review Am J Cardiol 97 2006 52C 60C